David Moller joins as Chief Scientific Officer and Steve Bryant as Chief Business Officer, adding deep expertise to executive teamSEATTLE (BUSINESS WIRE) Variant Bio, a genomics-driven drug discovery company, is transitioning from a company that focused on identifying genomic variants that uncover the basis of dis.
Results support the development of PXL770 in a Phase 2 clinical program for ADPKD Regulatory News: POXEL SA (Paris:POXEL) (Euronext: POXEL FR0012432516), a clinical stage biopharmaceutical company
POXEL SA (Euronext POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis
Poxel Announces the Formation of its Scientific Advisory Board for Rare Metabolic Diseases financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.
Poxel Reports Financial Results for Full Year 2020 and Provides Corporate Update apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.